DEST vs. HEMO, C4XD, OBD, ONC, SAR, SBTX, OPTI, OBI, NSCI, and SNG
Should you be buying Destiny Pharma stock or one of its competitors? The main competitors of Destiny Pharma include Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), Oxford BioDynamics (OBD), Oncimmune (ONC), Sareum (SAR), SkinBioTherapeutics (SBTX), OptiBiotix Health (OPTI), Ondine Biomedical (OBI), NetScientific (NSCI), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals (LON:HEMO) and Destiny Pharma (LON:DEST) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.
Destiny Pharma has higher revenue and earnings than Hemogenyx Pharmaceuticals. Destiny Pharma is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Destiny Pharma received 20 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 60.48% of users gave Destiny Pharma an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 27.3% of Destiny Pharma shares are held by institutional investors. 11.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Comparatively, 24.7% of Destiny Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Hemogenyx Pharmaceuticals has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500. Comparatively, Destiny Pharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
In the previous week, Destiny Pharma had 2 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 5 mentions for Destiny Pharma and 3 mentions for Hemogenyx Pharmaceuticals. Destiny Pharma's average media sentiment score of 1.54 beat Hemogenyx Pharmaceuticals' score of 0.26 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the media.
Hemogenyx Pharmaceuticals' return on equity of -67.29% beat Destiny Pharma's return on equity.
Summary
Destiny Pharma beats Hemogenyx Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Get Destiny Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DEST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Destiny Pharma Competitors List
Related Companies and Tools
